FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:2619-2621 June 15, 2006 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: Trastuzumab is a monoclonal antibody against HER2, a member of the epidermal growth factor receptor (EGFR) family, that improves the outcome of HER2-positive breast cancer.¹ Preclinical data have demonstrated that trastuzumab is effective in non–small-cell lung cancer, with additive or synergistic effects with various cytotoxic agents. However, trials of trastuzumab or other HER2-targeted agents, such as pertuzumab, failed to demonstrate clinical benefit in non–small-cell lung cancer when administered as monotherapy or combined with chemotherapy.²

In these studies, HER2 status was assessed by immunohistochemical analysis, a method that is not optimal.³ Moreover, the few patients whose tumors had . . . [Full Text of this Article]

This article has been cited by other articles:

• Cappuzzo, F., Janne, P. A., Skokan, M., Finocchiaro, G., Rossi, E., Ligorio, C., Zucali, P. A., Terracciano, L., Toschi, L., Roncalli, M., Destro, A., Incarbone, M., Alloisio, M., Santoro, A., Varella-Garcia, M. (2009). MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol 20: 298-304 [Abstract] [Full Text]  
• Cappuzzo, F., Ligorio, C., Janne, P. A., Toschi, L., Rossi, E., Trisolini, R., Paioli, D., Holmes, A. J., Magrini, E., Finocchiaro, G., Bartolini, S., Cancellieri, A., Ciardiello, F., Patelli, M., Crino, L., Varella-Garcia, M. (2007). Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization-Positive/Phospho-Akt-Positive or Never Smoker Patients With Advanced Non-Small-Cell Lung Cancer: The ONCOBELL Trial. JCO 25: 2248-2255 [Abstract] [Full Text]  
• Toschi, L., Cappuzzo, F. (2007). Understanding the New Genetics of Responsiveness to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. The Oncologist 12: 211-220 [Abstract] [Full Text]  
• Ono, M., Kuwano, M. (2006). Molecular Mechanisms of Epidermal Growth Factor Receptor (EGFR) Activation and Response to Gefitinib and Other EGFR-Targeting Drugs. Clin. Cancer Res. 12: 7242-7251 [Abstract] [Full Text]  
• Meric-Bernstam, F., Hung, M.-C. (2006). Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy.. Clin. Cancer Res. 12: 6326-6330 [Abstract] [Full Text]  
• Ikediobi, O. N., Davies, H., Bignell, G., Edkins, S., Stevens, C., O'Meara, S., Santarius, T., Avis, T., Barthorpe, S., Brackenbury, L., Buck, G., Butler, A., Clements, J., Cole, J., Dicks, E., Forbes, S., Gray, K., Halliday, K., Harrison, R., Hills, K., Hinton, J., Hunter, C., Jenkinson, A., Jones, D., Kosmidou, V., Lugg, R., Menzies, A., Mironenko, T., Parker, A., Perry, J., Raine, K., Richardson, D., Shepherd, R., Small, A., Smith, R., Solomon, H., Stephens, P., Teague, J., Tofts, C., Varian, J., Webb, T., West, S., Widaa, S., Yates, A., Reinhold, W., Weinstein, J. N., Stratton, M. R., Futreal, P. A., Wooster, R. (2006). Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Molecular Cancer Therapeutics 5: 2606-2612 [Abstract] [Full Text]